Belite Bio (NASDAQ:BLTE) CFO Hao-Yuan Chuang Sells 367 Shares

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) CFO Hao-Yuan Chuang sold 367 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $180.35, for a total transaction of $66,188.45. Following the completion of the transaction, the chief financial officer directly owned 93,433 shares in the company, valued at $16,850,641.55. This trade represents a 0.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Belite Bio Price Performance

NASDAQ:BLTE opened at $162.80 on Friday. The firm has a 50-day moving average of $152.50 and a 200-day moving average of $159.86. The company has a market cap of $6.53 billion, a PE ratio of -59.63 and a beta of -1.22. Belite Bio, Inc. Sponsored ADR has a one year low of $60.00 and a one year high of $200.00.

Belite Bio (NASDAQ:BLTE) last posted its earnings results on Tuesday, June 30th. The company reported ($0.54) earnings per share for the quarter. On average, equities research analysts expect that Belite Bio, Inc. Sponsored ADR will post -3.17 earnings per share for the current fiscal year.

Belite Bio News Summary

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Quarterly loss was narrower than expected. Belite Bio reported second-quarter 2026 EPS of -$0.54, beating the analyst consensus of -$0.73 by $0.19. The earnings surprise may support the stock by suggesting better-than-expected cost control or operating performance. Belite Bio quarterly earnings results
• Positive Sentiment: HC Wainwright sees substantial upside potential. The research firm issued a bullish forecast for BLTE, which could improve investor sentiment toward Belite Bio’s pipeline and long-term prospects. The report’s headline did not provide a specific price target in the available information. HC Wainwright forecast for Belite Bio
• Neutral Sentiment: Management provided a second-quarter financial and corporate update. Belite Bio released unaudited results for the quarter ended June 30, 2026, and discussed its business as it advances therapies for degenerative retinal diseases. Investors will likely focus on pipeline milestones, regulatory progress and cash resources from the update. Belite Bio second-quarter 2026 results and corporate update
• Negative Sentiment: CEO and CFO both sold small portions of their holdings. CEO Yu-Hsin Lin sold 365 shares and CFO Hao-Yuan Chuang sold 367 shares at an average price of $180.35. The transactions reduced their direct holdings by only 0.21% and 0.39%, respectively, limiting the significance, but simultaneous executive sales can still create a modest negative sentiment signal. Belite Bio CEO insider sale filing

Hedge Funds Weigh In On Belite Bio

A number of large investors have recently made changes to their positions in BLTE. Royal Bank of Canada lifted its holdings in Belite Bio by 7.9% during the 1st quarter. Royal Bank of Canada now owns 2,257 shares of the company’s stock worth $360,000 after purchasing an additional 165 shares in the last quarter. Bank of America Corp DE increased its position in shares of Belite Bio by 28.1% during the third quarter. Bank of America Corp DE now owns 1,171 shares of the company’s stock valued at $87,000 after buying an additional 257 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Belite Bio by 28,200.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company’s stock worth $45,000 after buying an additional 282 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Belite Bio in the 4th quarter worth approximately $103,000. Finally, Persistent Asset Partners Ltd bought a new position in Belite Bio in the 4th quarter valued at $108,000. 0.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on BLTE shares. Zacks Research raised Belite Bio from a “hold” rating to a “strong-buy” rating in a report on Monday, July 20th. Truist Financial set a $217.00 target price on Belite Bio in a research note on Friday, May 22nd. Benchmark reaffirmed a “buy” rating on shares of Belite Bio in a research report on Friday. Cantor Fitzgerald increased their price target on Belite Bio from $266.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, HC Wainwright lifted their price objective on Belite Bio from $200.00 to $214.00 and gave the stock a “buy” rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $205.80.

Belite Bio Company Profile

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.